Cellular heterogeneity of mesenchymal stem/stromal cells in the bone marrow
Y Mabuchi, C Okawara, S Méndez-Ferrer… - Frontiers in cell and …, 2021 - frontiersin.org
Mesenchymal stem/stromal cells (MSCs) are present in various body tissues and help in
maintaining homeostasis. The stemness of MSCs has been evaluated in vitro. In addition …
maintaining homeostasis. The stemness of MSCs has been evaluated in vitro. In addition …
Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease
Drug repurposing has been shown to bring safe medications to new patient populations, as
recently evidenced by the COVID-19 pandemic. We investigated whether we could use …
recently evidenced by the COVID-19 pandemic. We investigated whether we could use …
Cutaneous wound healing using polymeric surgical dressings based on chitosan, sodium hyaluronate and resveratrol. A preclinical experimental study
C Berce, MS Muresan, O Soritau, B Petrushev… - Colloids and Surfaces B …, 2018 - Elsevier
Wound healing is a complex and dynamic process that involves modifying the wound
environment depending on the patient's health status. Scar formation depends on many …
environment depending on the patient's health status. Scar formation depends on many …
Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis
P Teodorescu, S Pasca, A Jurj… - Journal of Cellular …, 2020 - Wiley Online Library
Primary myelofibrosis (PMF) is a Ph‐negative myeloproliferative neoplasm (MPN),
characterized by advanced bone marrow fibrosis and extramedullary haematopoiesis. The …
characterized by advanced bone marrow fibrosis and extramedullary haematopoiesis. The …
Mesenchymal stem cells in myeloproliferative disorders–focus on primary myelofibrosis
SE Selicean, C Tomuleasa, R Grewal… - Leukemia & …, 2019 - Taylor & Francis
Primary myelofibrosis (PMF) is the most aggressive Philadelphia-negative (Ph-)
myeloproliferative neoplasm (MPN), characterized by bone marrow (BM) insufficiency …
myeloproliferative neoplasm (MPN), characterized by bone marrow (BM) insufficiency …
Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?
S Boca, C Berce, A Jurj, B Petrushev, L Pop… - Medical …, 2017 - Elsevier
Alopecia is a dermatological condition for which Janus kinase (JAK) inhibitors have recently
emerged as potential therapy options, but with limited practical use because of the systemic …
emerged as potential therapy options, but with limited practical use because of the systemic …
Persistent basophilia may suggest an “accelerated phase” in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia
J Dobrowolski, S Pasca, P Teodorescu… - Frontiers in …, 2019 - frontiersin.org
Basophils are white blood cells that play an important role in the human immune system.
These cells physiologically increase in number in immune response to certain allergies …
These cells physiologically increase in number in immune response to certain allergies …
Cancer-associated fibroblasts in acute leukemia
L Gu, P Liao, H Liu - Frontiers in Oncology, 2022 - frontiersin.org
Although the prognosis for acute leukemia has greatly improved, treatment of
relapsed/refractory acute leukemia (R/R AL) remains challenging. Recently, increasing …
relapsed/refractory acute leukemia (R/R AL) remains challenging. Recently, increasing …
Overview of the side-effects of FDA-and/or EMA-approved targeted therapies for the treatment of hematological malignancies
C Constantinescu, S Pasca, AA Zimta, T Tat… - Journal of Clinical …, 2020 - mdpi.com
In the last decade there has been tremendous effort in offering better therapeutic
management strategies to patients with hematologic malignancies. These efforts have …
management strategies to patients with hematologic malignancies. These efforts have …
RETRACTED ARTICLE: Castleman's disease in the HIV-endemic setting
ER Mahroug, C Sher-Locketz… - Cancer Management …, 2018 - Taylor & Francis
Mahroug E, Sher-Locketz C, Desmirean M, et al. Cancer Manag Res. 2018; 10: 4553—
4563. The Editor-in-Chief and Publisher of Cancer Management and Research wish to …
4563. The Editor-in-Chief and Publisher of Cancer Management and Research wish to …